Newron Pharmaceuticals S.p.A. | Finanzwire

Basculer en Français

9788	Companies
196128	Keywords
127163	Articles
104293	Press releases

Headlines Articles Press releases Newron Pharmaceuticals S.p.A.

Home
Companies
Newron Pharmaceuticals S.p.A.

BRIEF

published on 02/03/2026 at 07:05, 4 hours 39 minutes ago

Newron Pharmaceuticals Highlights Benefits of Evenamide for Schizophrenia

Clinical Trials Schizophrenia Newron Pharmaceuticals Evenamide Treatment-resistant
PRESS RELEASE

published on 02/03/2026 at 07:00, 4 hours 44 minutes ago

Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia
Newron Pharmaceuticals S.p.A. announces publication highlighting Evenamide as adjunctive treatment in schizophrenia. Scientific evidence supports unique approach

Schizophrenia Publication Newron Pharmaceuticals Evenamide Adjunctive Treatment
BRIEF

published on 01/07/2026 at 07:05, 27 days 4 hours ago

Clinical Trial for Evenamide in Japan Commences

Phase III Trial Newron Pharmaceuticals Evenamide Schizophrenia Treatment EA Pharma
PRESS RELEASE

published on 01/07/2026 at 07:00, 27 days 4 hours ago

Newron Pharmaceuticals S.p.A.: EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
Newron Pharmaceuticals S.p.A. announces Phase III Clinical Trial initiation with Evenamide, a novel Schizophrenia treatment in Japan, led by EA Pharma, a subsidiary of Eisai

Schizophrenia Newron Pharmaceuticals Evenamide Phase III EA Pharma
BRIEF

published on 01/06/2026 at 07:05, 28 days 4 hours ago

Newron Pharmaceuticals Strengthens IP Portfolio for Evenamide

Patent Schizophrenia Newron Pharmaceuticals Evenamide Glutamate Modulation
PRESS RELEASE

published on 01/06/2026 at 07:00, 28 days 4 hours ago

Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent
Newron Pharmaceuticals obtains new EU Composition of Matter Patent EP4615820 for Evenamide, extending exclusivity into 2044

Patent Intellectual Property Schizophrenia Newron Pharmaceuticals Evenamide
BRIEF

published on 12/08/2025 at 07:05, 1 month 26 days ago

Newron Launches US Phase III Study on Evenamide for Schizophrenia

Clinical Trial Schizophrenia Newron Pharmaceuticals Evenamide Phase III Study
PRESS RELEASE

published on 12/08/2025 at 07:00, 1 month 26 days ago

Newron announces the US initiation of its ENIGMA-TRS 2 Phase III global clinical study with evenamide as an add-on therapy for patients with treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals initiates ENIGMA-TRS 2 Phase III global clinical study in US for treatment-resistant schizophrenia with evenamide as add-on therapy. Expecting results by Q4 2026

Newron Pharmaceuticals Evenamide Phase III Treatment-resistant Schizophrenia ENIGMA-TRS 2
BRIEF

published on 10/02/2025 at 07:05, 4 months 1 day ago

Newron Pharmaceuticals Highlights Evenamide at ECNP Congress 2025

Clinical Trial Schizophrenia Newron Pharmaceuticals Evenamide ECNP Congress
PRESS RELEASE

published on 10/02/2025 at 07:00, 4 months 1 day ago

Newron to present new analyses from and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 38th ECNP Congress 2025
Newron Pharmaceuticals to present new analyses and updates on evenamide as treatment for schizophrenia at the 38th ECNP Congress 2025

Clinical Program Schizophrenia Newron Pharmaceuticals Evenamide ECNP Congress

1 2 ... 7

Accesswire

Published on 02/03/2026 at 11:30, 14 minutes ago

Caldwell Strengthens Life Sciences and Healthcare Practice with Addition of Dr. Christoph Themel as Partner
Published on 02/03/2026 at 09:01, 2 hours 43 minutes ago

Star Copper Completes Copperline Field Program with Drill Permit Submitted for 2026
Published on 02/02/2026 at 23:55, 11 hours 49 minutes ago

2026 Tunkillia Development Drilling Programs Begin
Published on 02/02/2026 at 23:55, 11 hours 49 minutes ago

55 North Mining Announces Winter Exploration Drill Program at Last Hope Gold Project
Published on 02/02/2026 at 23:25, 12 hours 19 minutes ago

Western Announces Sale of GlassMasters Investment

View all ACCESSWIRE

EQS Group

Published on 02/03/2026 at 11:15, 28 minutes ago

EQS-Adhoc: hGears AG Group: Preliminary revenue and adjusted EBITDA for 2025 slightly above Management’s guidance; free cash flow affected by reclassification effect
Published on 02/03/2026 at 11:05, 38 minutes ago

2026 International AI Safety Report Charts Rapid Changes and Emerging Risks
Published on 02/03/2026 at 10:05, 1 hour 38 minutes ago

Home and Kitchenware Brand Karaca Expands in Germany
Published on 02/03/2026 at 10:05, 1 hour 38 minutes ago

Hisense Named World's First Customer Centricity Lighthouse Factory in the TV Industry by World Economic Forum
Published on 02/03/2026 at 09:40, 2 hours 3 minutes ago

Lemon Learning Acquires Aidaxis to Expand Desktop Application Coverage

Les Echos

Published on 02/03/2026 at 08:00, 3 hours 44 minutes ago

EURAZEO & PANTHEON ESTABLISH A NEARLY €500 MILLION PRIVATE DEBT CONTINUATION VEHICLE
Published on 02/03/2026 at 08:00, 3 hours 44 minutes ago

Neoen launches three new solar farms in France with a total capacity of 230 MWp
Published on 02/02/2026 at 18:23, 17 hours 20 minutes ago

Monthly disclosure of the total number of shares and voting rights - January 2026
Published on 02/02/2026 at 18:00, 17 hours 44 minutes ago

Covivio - Information on total number of voting rights and share capital
Published on 02/02/2026 at 17:35, 18 hours 9 minutes ago

Disclosure of transactions in own shares from January 26 to January 30, 2026

View all LES ECHOS COMFI WIRE